Evidence map›Paper›PMID 38035077›Full record

ArticleFrontiers in immunology2023

Cerebrospinal fluid oligoclonal bands in Chinese patients with multiple sclerosis: the prevalence and its association with clinical features.

Xiang Zhang, Hongjun Hao, Tao Jin, Wei Qiu, Huan Yang, Qun Xue, Jian Yin, Ziyan Shi, Hai Yu, Xiaopei Ji and 17 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Frontiers in neurology · 2025
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Xiang ZhangDepartment of Neurology, Huashan Hospital, Fudan University and Institute of Neurology, Fudan University, National Center for Neurological Disorders, Shanghai, China.
Hongjun HaoDepartment of Neurology, Peking University First Hospital, Beijing, China.
Tao JinDepartment of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China.
Wei QiuDepartment of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Huan YangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Qun XueDepartment of Neurology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Jian YinDepartment of Neurology, Beijing Hospital, Beijing, China.
Ziyan ShiDepartment of Neurology, West China Hospital, Sichuan University, Chengdu, China.
Hai YuDepartment of Neurology, Huashan Hospital, Fudan University and Institute of Neurology, Fudan University, National Center for Neurological Disorders, Shanghai, China.
Xiaopei JiDepartment of Neurology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Xiaobo SunDepartment of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Qiuming ZengDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Xiaoni LiuDepartment of Neurology, Huashan Hospital, Fudan University and Institute of Neurology, Fudan University, National Center for Neurological Disorders, Shanghai, China.
Jingguo WangDepartment of Neurology, Huashan Hospital, Fudan University and Institute of Neurology, Fudan University, National Center for Neurological Disorders, Shanghai, China.
Huining LiDepartment of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China.
Xiaoyan HeDepartment of Neurology, The Xinjiang Uygur Autonomous Region People's Hospital, Urumqi, China.
Jing YangDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yarong LiDepartment of Neurology, Huashan Hospital, Fudan University and Institute of Neurology, Fudan University, National Center for Neurological Disorders, Shanghai, China.
Shuangshuang LiuDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Alexander Y LauDepartment of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Feng GaoDepartment of Neurology, Peking University First Hospital, Beijing, China.
Shimin HuDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Shuguang ChuDepartment of Radiology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Ding DingDepartment of Neurology, Huashan Hospital, Fudan University and Institute of Neurology, Fudan University, National Center for Neurological Disorders, Shanghai, China.
Hongyu ZhouDepartment of Neurology, West China Hospital, Sichuan University, Chengdu, China.
Haifeng LiDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Xiangjun ChenDepartment of Neurology, Huashan Hospital, Fudan University and Institute of Neurology, Fudan University, National Center for Neurological Disorders, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cerebrospinal fluid oligoclonal band (CSF-OCB) is an established biomarker in diagnosing multiple sclerosis (MS), however, there are no nationwide data on CSF-OCB prevalence and its diagnostic performance in Chinese MS patients, especially in the virtue of common standard operation procedure (SOP). Methods: With a consensus SOP and the same isoelectric focusing system, we conducted a nationwide multi-center study on OCB status in consecutively, and recruited 483 MS patients and 880 non-MS patients, including neuro-inflammatory diseases (NID, n = 595) and non-inflammatory neurological diseases (NIND, n=285). Using a standardized case report form (CRF) to collect the clinical, radiological, immunological, and CSF data, we explored the association of CSF-OCB positivity with patient characters and the diagnostic performance of CSF-OCB in Chinese MS patients. Prospective source data collection, and retrospective data acquisition and statistical data analysis were used. Findings: 369 (76.4%) MS patients were OCB-positive, while 109 NID patients (18.3%) and 6 NIND patients (2.1%) were OCB-positive, respectively. Time from symptom onset to diagnosis was significantly shorter in OCB-positive than that in OCB-negative MS patients (13.2 vs 23.7 months, P=0.020). The prevalence of CSF-OCB in Chinese MS patients was significantly higher in high-latitude regions (41°-50°N)(P=0.016), and at high altitudes (>1000m)(P=0.025). The diagnostic performance of CSF-OCB differentiating MS from non-MS patients yielded a sensitivity of 76%, a specificity of 87%. Interpretation: The nationwide prevalence of CSF-OCB was 76.4% in Chinese MS patients, and demonstrated a good diagnostic performance in differentiating MS from other CNS diseases. The CSF-OCB prevalence showed a correlation with high latitude and altitude in Chinese MS patients.

Indexed as

Multiple SclerosisEast Asian PeopleHumansOligoclonal BandsPrevalenceProspective StudiesRetrospective StudiesOligoclonal Bandscerebrospinal fluidChinadiagnostic performancemultiple sclerosisoligoclonal bandsprevalence

Identifiers

PMID38035077
PMCPMC10687400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.